Oxford BioDynamics at Shanghai Forum to expand Chinese partnerships
, a biotechnology company using the discovery and development of epigenetic markers in the pharmaceutical and biotech industries, is set to present at the China BIO Partnering Forum today in Shanghai.
The company’s Chief Scientific Officer Dr. Alexandre Akoulitchev will be hosting the talk, titled “EpiSwitch™ Biomarkers: Practical Applications For Predictive, Prognostic And Diagnostic Patient Stratifications."
The validated EpiSwitch™ biomarker applications, the focus of the presentation, have demonstrated “high efficacy in predictive, prognostic and diagnostic patient stratifications for lung, haematological, prostate, thyroid and skin cancers.”
Off this cutting edge biotechnology, the company has finalized its fifth collaboration agreement with “leading pharmaceutical companies” to develop biomarkers that can be predictive for immuno-oncology therapeutics.
Dr. Akoulitchev commented: "We are looking forward to establishing new partnerships for OBD's EpiSwitch™ technology in China.
Our experience includes working with American and European biopharmaceutical partners to enable precision medicine initiatives through the incorporation of our proprietary, epigenetic-based biomarker platform across the research and development value chain.”
For more news and updates on Oxford BioDynamics:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.